11th International AIDS Conference Vancouver, British Columbia — July 7-12, 1996

Int Conf AIDS 1996 Jul 7-12; 11:29 (abstract no. LB.B.6034)
Excler JL, Duliege AM, Clements ML, Salmon D, McNamara J, Fast P, Meignier B, Klein M, Plotkin SA; Pasteur Merieux Serums & Vaccins, France. Fax: 33.1.47.95.80.00.

Vaccination against HIV should evoke both neutralizing antibodies and cellular immune responses. No single antigen has yet demonstrated the ability to produce both types of responses. Nevertheless, glycoproteins administered with good adjuvants have been adept at inducing neutralizing antibodies against laboratory strains of HIV, whereas poxvirus vectors have induced CTL directed against HIV-infected cells. Accordingly, Pasteur-Merieux-Connaught and the Chiron Corporation have collaborated to develop a prime-boost protocol. Clinical trials have been conducted under the aegis of the NIAID and the French National AIDS Agency combined regimen in which seronegative volunteers are primed with canarypox vectors containing several genes of HIV-1, and then given recall injections of gp120 envelope protein adjuvanted with MF-59. Both neutralizing antibodies and HIV protein specific CTL responses have been generated in volunteers, as will be described.

960707
LBB6034

Copyright © 1996 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.